Sugiyama Y - Search Results

1

Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product.

Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Ozawa S, et al. Among authors: sugiyama y. Cancer Chemother Pharmacol. 1988;21(3):185-90. doi: 10.1007/BF00262767. Cancer Chemother Pharmacol. 1988. PMID: 3129204

2

[Quantitative analysis of cell-kill effects of anticancer drugs: consideration of both in vitro and in vivo experimental systems].

Sugiyama Y, Kobayashi T, Inaba M. Sugiyama Y, et al. Gan To Kagaku Ryoho. 1987 Dec;14(12):3183-98. Gan To Kagaku Ryoho. 1987. PMID: 3318699 Review. Japanese.

3

Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up.

Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, Kobayashi T. Mitsuhashi Y, et al. Among authors: sugiyama y. Cancer Chemother Pharmacol. 1990;27(1):20-6. doi: 10.1007/BF00689271. Cancer Chemother Pharmacol. 1990. PMID: 2245489

4

Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells.

Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M. Ozawa S, et al. Among authors: sugiyama y. Cancer Res. 1989 Jul 15;49(14):3823-8. Cancer Res. 1989. PMID: 2736524

5

In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve.

Mitsuhashi Y, Inaba M, Sugiyama Y, Kobayashi T. Mitsuhashi Y, et al. Among authors: sugiyama y. Cancer. 1992 Nov 15;70(10):2540-6. doi: 10.1002/1097-0142(19921115)70:10<2540::aid-cncr2820701024>3.0.co;2-2. Cancer. 1992. PMID: 1330284

6

Pharmacokinetics of CPT-11 in rhesus monkeys.

Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y. Inaba M, et al. Among authors: sugiyama y. Cancer Chemother Pharmacol. 1998;41(2):103-8. doi: 10.1007/s002800050715. Cancer Chemother Pharmacol. 1998. PMID: 9443622

7

Saturable process involved in active efflux of vincristine as a mechanism of multidrug resistance in P388 leukemia cells.

Watanabe T, Inaba M, Sugiyama Y. Watanabe T, et al. Among authors: sugiyama y. Pharm Res. 1989 Aug;6(8):690-6. doi: 10.1023/a:1015986405834. Pharm Res. 1989. PMID: 2813261

8

Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.

Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y. Fuse E, et al. Among authors: sugiyama y. J Natl Cancer Inst. 1994 Jul 6;86(13):989-96. doi: 10.1093/jnci/86.13.989. J Natl Cancer Inst. 1994. PMID: 8024657

9

Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations.

Nakai D, Fuse E, Suzuki H, Inaba M, Sugiyama Y. Nakai D, et al. Among authors: sugiyama y. J Drug Target. 1996;3(6):443-53. doi: 10.3109/10611869609015964. J Drug Target. 1996. PMID: 8863137

10

Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics.

Fuse E, Kobayashi T, Inaba M, Sugiyama Y. Fuse E, et al. Among authors: sugiyama y. Cancer Treat Rev. 1995 Mar;21(2):133-57. doi: 10.1016/0305-7372(95)90024-1. Cancer Treat Rev. 1995. PMID: 7758004 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,690 results

Search Page

Filters